322 related articles for article (PubMed ID: 25670082)
1. Recurrent DGCR8, DROSHA, and SIX homeodomain mutations in favorable histology Wilms tumors.
Walz AL; Ooms A; Gadd S; Gerhard DS; Smith MA; Guidry Auvil JM; Meerzaman D; Chen QR; Hsu CH; Yan C; Nguyen C; Hu Y; Bowlby R; Brooks D; Ma Y; Mungall AJ; Moore RA; Schein J; Marra MA; Huff V; Dome JS; Chi YY; Mullighan CG; Ma J; Wheeler DA; Hampton OA; Jafari N; Ross N; Gastier-Foster JM; Perlman EJ
Cancer Cell; 2015 Feb; 27(2):286-97. PubMed ID: 25670082
[TBL] [Abstract][Full Text] [Related]
2. Mutations in the SIX1/2 pathway and the DROSHA/DGCR8 miRNA microprocessor complex underlie high-risk blastemal type Wilms tumors.
Wegert J; Ishaque N; Vardapour R; Geörg C; Gu Z; Bieg M; Ziegler B; Bausenwein S; Nourkami N; Ludwig N; Keller A; Grimm C; Kneitz S; Williams RD; Chagtai T; Pritchard-Jones K; van Sluis P; Volckmann R; Koster J; Versteeg R; Acha T; O'Sullivan MJ; Bode PK; Niggli F; Tytgat GA; van Tinteren H; van den Heuvel-Eibrink MM; Meese E; Vokuhl C; Leuschner I; Graf N; Eils R; Pfister SM; Kool M; Gessler M
Cancer Cell; 2015 Feb; 27(2):298-311. PubMed ID: 25670083
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the mutational status of SIX1/2 and microRNA processing genes in paired primary and relapsed Wilms tumors and association with relapse.
Ciceri S; Montalvão-de-Azevedo R; Tajbakhsh A; Bertolotti A; Spagnuolo RD; Boschetti L; Capasso M; D'Angelo P; Serra A; Diomedi-Camassei F; Meli M; Nantron M; Quarello P; Buccoliero AM; Tamburini A; Ciniselli CM; Verderio P; Collini P; Radice P; Spreafico F; Perotti D
Cancer Gene Ther; 2021 Sep; 28(9):1016-1024. PubMed ID: 33281191
[TBL] [Abstract][Full Text] [Related]
4. Chromosomal anomalies at 1q, 3, 16q, and mutations of SIX1 and DROSHA genes underlie Wilms tumor recurrences.
Spreafico F; Ciceri S; Gamba B; Torri F; Terenziani M; Collini P; Macciardi F; Radice P; Perotti D
Oncotarget; 2016 Feb; 7(8):8908-15. PubMed ID: 26802027
[TBL] [Abstract][Full Text] [Related]
5. WT1 mutation and 11P15 loss of heterozygosity predict relapse in very low-risk wilms tumors treated with surgery alone: a children's oncology group study.
Perlman EJ; Grundy PE; Anderson JR; Jennings LJ; Green DM; Dome JS; Shamberger RC; Ruteshouser EC; Huff V
J Clin Oncol; 2011 Feb; 29(6):698-703. PubMed ID: 21189373
[TBL] [Abstract][Full Text] [Related]
6. Wilms tumour histology is determined by distinct types of precursor lesions and not epigenetic changes.
Fukuzawa R; Anaka MR; Heathcott RW; McNoe LA; Morison IM; Perlman EJ; Reeve AE
J Pathol; 2008 Aug; 215(4):377-87. PubMed ID: 18484682
[TBL] [Abstract][Full Text] [Related]
7. Altered binding affinity of SIX1-Q177R correlates with enhanced WNT5A and WNT pathway effector expression in Wilms tumor.
Stevenson MJ; Phanor SK; Patel U; Gisselbrecht SS; Bulyk ML; O'Brien LL
Dis Model Mech; 2023 Nov; 16(11):. PubMed ID: 37815464
[TBL] [Abstract][Full Text] [Related]
8. Recurrent somatic mutation in DROSHA induces microRNA profile changes in Wilms tumour.
Torrezan GT; Ferreira EN; Nakahata AM; Barros BD; Castro MT; Correa BR; Krepischi AC; Olivieri EH; Cunha IW; Tabori U; Grundy PE; Costa CM; de Camargo B; Galante PA; Carraro DM
Nat Commun; 2014 Jun; 5():4039. PubMed ID: 24909261
[TBL] [Abstract][Full Text] [Related]
9. Decreased E-cadherin expression correlates with higher stage of Wilms' tumors.
Safford SD; Freemerman AJ; Langdon S; Bentley R; Goyeau D; Grundy PE; Skinner MA
J Pediatr Surg; 2005 Feb; 40(2):341-8. PubMed ID: 15750927
[TBL] [Abstract][Full Text] [Related]
10. Loss or oncogenic mutation of DROSHA impairs kidney development and function, but is not sufficient for Wilms tumor formation.
Kruber P; Angay O; Winkler A; Bösl MR; Kneitz S; Heinze KG; Gessler M
Int J Cancer; 2019 Mar; 144(6):1391-1400. PubMed ID: 30367465
[TBL] [Abstract][Full Text] [Related]
11. The DGCR8 E518K mutation found in Wilms tumors leads to a partial miRNA processing defect that alters gene expression patterns and biological processes.
Vardapour R; Kehl T; Kneitz S; Ludwig N; Meese E; Lenhof HP; Gessler M
Carcinogenesis; 2022 Mar; 43(2):82-93. PubMed ID: 34919667
[TBL] [Abstract][Full Text] [Related]
12. Microdissecting the genetic events in nephrogenic rests and Wilms' tumor development.
Charles AK; Brown KW; Berry PJ
Am J Pathol; 1998 Sep; 153(3):991-1000. PubMed ID: 9736048
[TBL] [Abstract][Full Text] [Related]
13. Genetic changes associated with relapse in favorable histology Wilms tumor: A Children's Oncology Group AREN03B2 study.
Gadd S; Huff V; Skol AD; Renfro LA; Fernandez CV; Mullen EA; Jones CD; Hoadley KA; Yap KL; Ramirez NC; Aris S; Phung QH; Perlman EJ
Cell Rep Med; 2022 Jun; 3(6):100644. PubMed ID: 35617957
[TBL] [Abstract][Full Text] [Related]
14. Two candidate tumor suppressor genes, MEOX2 and SOSTDC1, identified in a 7p21 homozygous deletion region in a Wilms tumor.
Ohshima J; Haruta M; Arai Y; Kasai F; Fujiwara Y; Ariga T; Okita H; Fukuzawa M; Hata J; Horie H; Kaneko Y
Genes Chromosomes Cancer; 2009 Dec; 48(12):1037-50. PubMed ID: 19760604
[TBL] [Abstract][Full Text] [Related]
15. A heterotrimer model of the complete Microprocessor complex revealed by single-molecule subunit counting.
Herbert KM; Sarkar SK; Mills M; Delgado De la Herran HC; Neuman KC; Steitz JA
RNA; 2016 Feb; 22(2):175-83. PubMed ID: 26683315
[TBL] [Abstract][Full Text] [Related]
16. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group.
Grundy PE; Breslow NE; Li S; Perlman E; Beckwith JB; Ritchey ML; Shamberger RC; Haase GM; D'Angio GJ; Donaldson M; Coppes MJ; Malogolowkin M; Shearer P; Thomas PR; Macklis R; Tomlinson G; Huff V; Green DM;
J Clin Oncol; 2005 Oct; 23(29):7312-21. PubMed ID: 16129848
[TBL] [Abstract][Full Text] [Related]
17. Genomic profiling maps loss of heterozygosity and defines the timing and stage dependence of epigenetic and genetic events in Wilms' tumors.
Yuan E; Li CM; Yamashiro DJ; Kandel J; Thaker H; Murty VV; Tycko B
Mol Cancer Res; 2005 Sep; 3(9):493-502. PubMed ID: 16179496
[TBL] [Abstract][Full Text] [Related]
18. Wilms tumor: an update.
Al-Hussain T; Ali A; Akhtar M
Adv Anat Pathol; 2014 May; 21(3):166-73. PubMed ID: 24713986
[TBL] [Abstract][Full Text] [Related]
19. Nephron Progenitor But Not Stromal Progenitor Cells Give Rise to Wilms Tumors in Mouse Models with β-Catenin Activation or Wt1 Ablation and Igf2 Upregulation.
Huang L; Mokkapati S; Hu Q; Ruteshouser EC; Hicks MJ; Huff V
Neoplasia; 2016 Feb; 18(2):71-81. PubMed ID: 26936393
[TBL] [Abstract][Full Text] [Related]
20. Association of miRNA biosynthesis genes
Wen J; Lv Z; Ding H; Fang X; Sun M
Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29654164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
